Figure 2
(A) The TTNT of the MM patients treated with elotuzumab according to a three-point scoring system: 0 points (black), 1 point (red) and 2 points (blue). Total scores were calculated according to the lymphocyte counts (0 points when ≥ 1400/μL and 1 point when < 1400/μL) and κ/λ ratio (0 points when 0.1–10 and 1 point when < 0.1 or ≥ 10) before elotuzumab treatment (model 1). The median TTNT (months) and 95% CI are shown in the figure. The TTNT values were corrected by the prior regimen numbers and the prior use of daratumumab. NA indicates not applicable. (B) The overall survival (OS) of the MM patients treated with elotuzumab according to the scoring system of model 1: 0 points (black), 1 point (red) and 2 points (blue). Only the patients with the first use of elotuzumab were analyzed. The 2-year OS of each group and 95% CI are shown in the figure. The OS values were corrected by the prior regimen numbers and the prior use of daratumumab. (C) The TTNT of the MM patients treated with elotuzumab according to the scoring system of model 2: 0 points (black), 1 point (red) and 2 points (blue). Total scores were calculated according to the lymphocyte counts (0 points when ≥ 1400/μL and 1 point when < 1400/μL) and β2 microglobulin (B2MG; 0 points when 5.5 mg/L and 1 point when ≥ 5.5 mg/L) before elotuzumab treatment (model 2). The median TTNT (months) and 95% CI are shown in the figure. The TTNT values were corrected by the prior use of daratumumab. NA indicates not applicable. (D) The overall survival (OS) of the MM patients treated with elotuzumab according to the scoring system of model 2: 0 points (black), 1 point (red) and 2 points (blue). Only the patients with the 1st use of elotuzumab were analyzed. The 2-year OS of each group and 95% CI are shown in the figure. The OS values were corrected by the prior use of daratumumab. The number of patients at risk in each group is shown in the lower panel of each figure. CI: confidence interval.
